The $45-million research program at the Veterans Administration Greater Los Angeles Healthcare System (VAGLAHS) is slowly recovering after being abruptly shut down in March in an unprecedented sanction over regulations safeguarding patients in studies.1

"This might be the thing that wakes everybody up."

--Stephen Pandol

All 322 laboratory and animal studies, and more than 300 of the original 352 human clinical studies have been authorized to resume, leaving about 50 human studies in various stages of review. In addition, 29 new human studies have been approved since the shutdown. "It's quite a laborious process putting them through this review," says acting research director Marguerite Hays, who is on leave from the Palo Alto, Calif. VA medical center.

"The difficulty has been that it takes an awful lot of work to re-review all the protocols as though they have never been reviewed before," says John R. Feussner, VA...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!